Blood Plasma Derivatives Market Size to Reach US$ 51.12 Billion by 2028, Growing at a CAGR of 9.4%

Blood Plasma Derivatives Market Size to Reach US$ 51.12 Billion by 2028, Growing at a CAGR of 9.4%

Blood Plasma Derivatives Market size is projected to reach US$ 51.12 Billion by 2028 from US$ 29.89 Billion in 2022. The market is anticipated to register a CAGR of 9.4% from 2022 to 2028. Rising demand for plasma-based therapies supports the expansion of blood plasma derivative products. Advances in plasma collection and fractionation processes are expected to create further growth opportunities.

Download Sample PDF @ https://www.theinsightpartners.com/sample/TIPRE00007250

Key Players Analysis:

Grifols SA
SK Plasma Co Ltd
Octapharma AG
Monobind Inc
Intas Pharmaceuticals Ltd
Fusion Health Care Pvt Ltd
Takeda Pharmaceutical Co Ltd
CSL Behring LLC
LFB SA
Kedrion SpA

The blood plasma derivatives market includes albumin, Factor VIII, Factor IX, immunoglobulins, and hyperimmune globulins, with applications in hemophilia, hypogammaglobulinemia, immunodeficiency diseases, and von Willebrand disease. These product and application categories address varied therapeutic needs. Companies including Grifols SA, CSL Behring LLC, Takeda Pharmaceutical Company, Octapharma AG, and Kedrion SpA are part of the market’s broad competitive landscape.

Market Segmentation:

  • By Type (Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin)
  • By Application (Hemophilia, Hypogammaglobulinemia, Immunodeficiency Diseases, von Willebrand

Blood Plasma Derivatives Market Dynamics, Regional Analysis, and Future Outlook –

Market Drivers:

Rising demand for immunoglobulins, albumin, and clotting factor therapies is driving the blood plasma derivatives market. Increasing diagnosis of immune deficiencies, bleeding disorders, and selected critical conditions, together with expanding access to plasma-derived medicines, supports market demand.

Market Opportunities:

Opportunities include expanded plasma collection, improved fractionation and purification technologies, manufacturing capacity investment, and greater access to immunoglobulin and albumin therapies. Emerging markets and development of more efficient plasma processing methods may create additional growth opportunities.

Market Challenges:

Plasma collection constraints, high manufacturing costs, complex purification processes, stringent regulatory requirements, and supply shortages can limit market expansion. Donor recruitment, infectious disease screening, dependence on plasma supply networks, and competition for fractionation capacity also create challenges.

Regional Analysis:

North America is a major market supported by established plasma collection networks and advanced fractionation facilities. Europe has a developed plasma-derived medicines sector and regulatory infrastructure. Asia Pacific offers opportunities through growing healthcare demand and investment in domestic capacity. Other regions may depend more heavily on imports and face access limitations.

Future Analysis and Forecast:

The market is expected to benefit from demand for immunoglobulins, albumin, and coagulation therapies. Investment in plasma collection, fractionation capacity, and process efficiency may improve supply. Future growth will depend on donor availability, manufacturing expansion, reimbursement, regulatory compliance, and the development of alternative therapies where clinically appropriate.

Recent Industry Developments:

Industry developments include investment in plasma collection centers, fractionation facilities, purification technologies, and production capacity for immunoglobulins and other plasma-derived medicines. Manufacturers are also working to improve supply resilience and processing efficiency. Specific acquisitions, capacity expansions, and regulatory approvals should be verified through official announcements.

Get Full Report Copy @ https://www.theinsightpartners.com/buy/TIPRE00007250

Developments in the blood plasma derivatives market are highlighted by major infrastructure expansions in commercial plasma collection networks and significant process engineering improvements in plasma fractionation efficiency. Fractionation companies are deploying advanced automated collection technologies and state-of-the-art purification protocols to maximize the yield of essential plasma proteins—such as immunoglobulins, albumin, and clotting factors—from every liter of donated plasma. Furthermore, biopharmaceutical firms are investing heavily in advanced pathogen-reduction technologies and viral inactivation steps to achieve unprecedented safety profiles for all plasma-derived therapeutic products distributed across global healthcare systems.

About Us

The Insight Partners, we provide comprehensive analysis and insights into market trends that empower businesses to make informed decisions. Our reports are designed to equip stakeholders with the necessary information to navigate the complexities of various industries, including healthcare, technology, and finance. We are dedicated to delivering high-quality research that enables our clients to achieve their strategic objectives.

Contact Us:

Contact Person: Ankit Mathur

E-mail: [email protected]

Phone: +1-646-491-9876

Avatar photo
Author: Weida Isles
Writer and editor of the PNP Media.